Clinical experience and safety of ferric carboxymaltose for treating iron deficiency in heart failure patients with mildly reduced and preserved left ventricular ejection fraction.
Prognostic impact of co-morbidities on long-term prognosis in patients with reduced and preserved ejection fraction following acute myocardial infarction
Speaker:
Assistant Professor L. Savic (Belgrade, RS)
Soluble transferrin receptor as a marker of tissue iron deficiency: impact on health-related quality of life in patients with heart failure without systemic iron deficiency or anaemia
Speaker:
Mr R. Ramos Polo (Hospitalet De Llobregat, ES)
Infection risk with ferric derisomaltose compared to standard of care in patients with heart failure and iron deficiency: a prespecified analysis of the IRONMAN trial